Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pasireotide LAR in Severe Polycystic Liver Disease (SOM230)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Mayo Clinic
Sponsor:
Information provided by (Responsible Party):
Marie Hogan, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01670110
First received: August 17, 2012
Last updated: May 8, 2014
Last verified: May 2014

August 17, 2012
May 8, 2014
August 2012
December 2015   (final data collection date for primary outcome measure)
  • Absolute change in liver volume [ Time Frame: baseline to month 12 ] [ Designated as safety issue: No ]
    MRI will be used to measure liver volume.
  • Percent change in liver volume [ Time Frame: baseline to 12 months ] [ Designated as safety issue: No ]
    MRI will be used to measure liver volume
Same as current
Complete list of historical versions of study NCT01670110 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pasireotide LAR in Severe Polycystic Liver Disease
A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease

The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.

Pasireotide (SOM230) is a novel multi-receptor-targeted analog that has high affinity for four of the five SST receptor subtypes (SSTr1, SSTr2, SSTr3 and SSTr5); it has a 40-fold higher affinity and 158-fold higher functional activity for the SST5 receptor than octreotide. Because of its broad receptor binding profile, pasireotide may be more potent in Polycystic Liver Disease (PLD) than octreotide. In this randomized double blind placebo controlled trial the investigators will compare SOM230 treatment to placebo for 12 months in patients with PLD. The primary endpoints will be assessed at 12 months and patients receiving placebo then crossed over to SOM230, permitting all participants to receive SOM230 for the subsequent two years. Magnetic resonance imaging (MRI) will be used to assess liver volume - the primary endpoint, which will be assessed at baseline, end of years 1 and 3. This study will assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life over 12 months. (The investigators will not be assessing efficacy at 24 months.) The therapy way be effective in PLD but also may prove to be effective for many more patients with Polycystic Kidney Disease (PKD) which will be evaluated using eGFR and kidney volume using MRI.

The investigators plan to add other sub-sites in other locations.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Somatostatin Analogs
  • Polycystic Liver Disease
  • Autosomal Dominant Polycystic Kidney Disease
  • Autosomal Dominant Polycystic Liver Disease
  • Drug: Pasireotide LAR
    Injectible, 60mg per month
  • Drug: Placebo
    To be injected once per month
  • Active Comparator: Pasireotide LAR (SOM230)
    Active Pasireotide LAR
    Intervention: Drug: Pasireotide LAR
  • Placebo Comparator: placebo injection
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
48
December 2016
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female Age ≥ 18 years.
  • Diagnosis of PLD associated with ADPKD (meeting the Modified Ravine's criteria) or isolated ADPLD (defined by the criteria described by Reynolds et al)
  • Severe PLD defined as a liver volume >4000mL or symptomatic disease due to mass effects from hepatic cysts (must be able to undergo MRI or CT scan to determine this).
  • Not a candidate for or declining surgical intervention.
  • Capable of providing informed consent.
  • Life expectancy ≥ 12 weeks
  • Patients with a known history of impaired fasting blood glucose (glucose >100 and <126) may be included at the discretion of the PI. These patients should be monitored closely throughout the trial and antihyperglycemic treatment adjusted as necessary. Patients that are deemed non eligible due to elevated glucose can be re-screened after adequate medical treatment.
  • Adequate end organ function as defined by:
  • Adequate bone marrow function:

    • WBC ≥ 2.5 x 109/L
    • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
    • Hb ≥ 9 g/dL
  • No evidence of significant liver disease:

    • Serum bilirubin ≤1.5 x ULN
    • INR < 1.3
    • ALT and AST ≤ 2 x ULN
  • Estimated glomerular filtration rate (eGFR) >30 ml/min/m2
  • Serum amylase and lipase ≤ 1.5 x ULN
  • Alkaline phosphatase ≤ 2.5 x ULN
  • Written informed consent obtained prior to any screening procedures
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures

Exclusion Criteria:

  • Patients will be considered ineligible for this study if they meet any of the following criteria:
  • Patients with a known hypersensitivity to SST analogs or any component of the pasireotide LAR or SQ formulations.
  • Patients with known malabsorption syndrome, short bowel or chologenic diarrhea not controlled by specific therapeutic means.
  • Patients with abnormal coagulation (PT or a PTT elevated by 30% above normal limits).
  • Patients on continuous anticoagulation therapy. Patients who were on anticoagulant therapy must complete a washout period of at least 10 days and have confirmed normal coagulation parameters before study inclusion.
  • Patients with symptomatic cholelithiasis.
  • Patients who are not biochemically euthyroid.
  • Patients with known history of hypothyroidism are eligible if they are on adequate and stable re-placement thyroid hormone therapy for at least 3 months.
  • Serum magnesium ≥ ULN
  • QT-related exclusion criteria:
  • QTcF at screening > 470 msec
  • Patients with a history of syncope or family history of idiopathic sudden death
  • Patients who have sustained or clinically significant cardiac arrhythmias
  • Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block
  • Patients with concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
  • Family history of long QT syndrome
  • Concomitant medications known to prolong the QT interval.
  • Potassium < or = to 3.5
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
  • Patients who have Uncontrolled diabetes as defined by HbA1c>8%* despite adequate therapy
  • Patients with the presence of active or suspected acute or chronic uncontrolled infection or with a history of immunodeficiency, including a positive HIV test result (ELISA and Western blot). An HIV test will not be required; however, previous medical history will be reviewed.
  • Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with this study treatment.
  • Liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis or chronic persistent hepatitis.
  • Baseline ALT or AST >3x ULN
  • Patients with life-threatening autoimmune and ischemic disorders.
  • Uncontrolled hypertension
  • Patients who have a history of a primary malignancy, with the exception of locally excised non-melanoma skin cancer and carcinoma in situ of uterine cervix. (Patients who have had no evidence of disease from primary cancer for 3 or more years are allowed to participate in the study.)
  • History of pancreatitis
  • Patients with a known history of hepatitis B or C
  • Presence of Hepatitis B surface antigen (HbsAg)
  • Presence of Hepatitis C antibody (anti-HCV)
  • Patients with a history of, or current, alcohol misuse/abuse within the past 12 months
  • Known gallbladder or bile duct disease, acute or chronic pancreatitis
  • Patients who have any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the Investigator or the Sponsor's Medical Monitor
  • Use of an investigational drug within 1 month prior to dosing
  • Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study
Both
18 Years and older
No
Contact: Angela Ihrke 507-538-2902 ihrke.angela@mayo.edu
Contact: Marie C Hogan, MD, PhD 507-284-2511 hogan.marie@mayo.edu
United States
 
NCT01670110
11-007405
Yes
Marie Hogan, Mayo Clinic
Mayo Clinic
Not Provided
Principal Investigator: Marie C Hogan, MD PhD Mayo Clinic
Mayo Clinic
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP